TRNS · XBRL financial data

Transcat financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TRNS's year ends in late March)

In thousands of dollars	FY 2021Mar 27, 2021	FY 2022Mar 26, 2022	FY 2023Mar 25, 2023	FY 2024Mar 30, 2024	FY 2025Mar 31, 2025	FY 2026Mar 28, 2026
Revenue	173,335	204,959	230,569	259,481	—	331,877
Cost of goods and services sold	127,217	146,520	162,214	175,675	—	223,573
Gross profit	46,118	58,439	68,355	83,806	—	108,304
General and administrative	17,302	23,647	27,346	35,315	—	52,276
Total operating expenses	35,045	44,296	52,107	64,025	—	95,041
Operating income (loss)	11,073	14,143	16,248	19,781	—	13,263
Interest income	—	0	0	808	—	23
Interest expense	—	810	2,417	1,835	—	4,602
Other income (expense)	—	(143)	(344)	(315)	—	(695)
Income tax expense (benefit)	2,191	1,810	2,799	4,792	—	2,613
Net income (loss)	7,791	11,380	10,688	13,647	—	5,376
Earnings per share, basic USD per share	1.05	1.52	1.42	1.66	—	0.58
Earnings per share, diluted USD per share	1.03	1.50	1.40	1.63	—	0.57
Weighted average shares, basic thousands of shares	7,423	7	7,551	8,239	—	9,334
Weighted average shares, diluted thousands of shares	7,548	8	7,645	8,352	—	9,380

Fiscal years (TRNS's year ends in late March)

In thousands of dollars	FY 2021Mar 27, 2021	FY 2022Mar 26, 2022	FY 2023Mar 25, 2023	FY 2024Mar 30, 2024	FY 2025Mar 31, 2025	FY 2026Mar 28, 2026
Cash and cash equivalents	560	1,396	1,531	19,646	—	4,942
Marketable securities	—	—	0	15,533	—	—
Accounts receivable	33,950	39,737	44,698	47,779	—	65,170
Inventory	11,636	12,712	16,929	17,418	—	13,705
Prepaid and other current assets	2,354	5,301	3,935	4,276	—	7,973
Total current assets	48,928	59,704	67,599	105,158	—	92,462
Property and equipment, net	22,203	26,439	29,064	38,944	50,024	57,801
Right-of-use asset	9,392	11,026	14,876	16,823	—	32,365
Goodwill	43,272	65,074	69,360	105,585	—	218,185
Total assets	132,116	177,762	195,749	287,552	—	480,487
Accounts payable	12,276	14,171	15,869	11,495	—	17,931
Current portion of long-term debt	2,067	2,161	2,248	2,339	—	0
Total current liabilities	25,142	27,710	28,318	33,499	—	39,628
Long-term debt	17,494	46,291	46,869	1,817	—	99,885
Lease liability, non-current	7,958	9,194	12,960	14,873	—	29,000
Total liabilities	57,038	91,586	96,119	62,383	—	179,868
Retained earnings	52,513	58,744	69,163	80,074	—	97,757
Total stockholders' equity	75,078	86,176	99,630	225,169	—	300,619
Total liabilities and equity	132,116	177,762	195,749	287,552	—	480,487
Common shares outstanding (cover page) thousands of shares	7,469	7,546	7,643	9,134	9,318	9,341

Fiscal years (TRNS's year ends in late March)

In thousands of dollars	FY 2021Mar 27, 2021	FY 2022Mar 26, 2022	FY 2023Mar 25, 2023	FY 2024Mar 30, 2024	FY 2025Mar 31, 2025	FY 2026Mar 28, 2026
Net income (loss)	7,791	11,380	10,688	13,647	—	5,376
Stock-based compensation	1,513	2,329	3,377	4,512	—	7,549
Depreciation and amortization	7,580	9,567	10,955	13,544	—	26,172
Net cash from operating activities	23,639	17,618	16,951	32,616	—	34,850
Purchases of property and equipment	6,617	10,152	9,414	13,280	—	15,298
Net cash from investing activities	(10,151)	(39,851)	(18,513)	(41,672)	—	(97,823)
Proceeds from issuing common stock	1,177	1,486	658	—	—	—
Share repurchases	3,049	6,683	447	4,906	—	469
Repayments of long-term debt	1,982	2,114	2,121	2,248	—	—
Net cash from financing activities	(12,655)	23,694	876	27,399	—	66,501
Net change in cash	61	836	135	18,115	—	3,425

SIC 3825 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3825 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Transcat	5,758	97,090	10,148*	9.4M	—	Q2 FY27 10-QSep 26, 2026
Aehr Test Systems	116,358	18,835*	1,832*	32.6M	—	Q4 FY26 10-KMay 29, 2026
EyePoint	110,458	507	(62,348)*	86.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Allient	42,088	153,770	13,954*	17.0M	—	Q2 FY26 10-QJun 30, 2026
Cohu	272,303	172,956	5,600*	47.3M	—	Q3 FY26 10-QSep 26, 2026
Cytek Biosciences	73,846	48,140	1,367*	130.0M	—	Q2 FY26 10-QJun 30, 2026
Senseonics Holdings	44,753	14,483	(30,138)*	52.9M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Pacific Biosciences of California	61,003	39,007	(35,583)*	310.8M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Mesa Laboratories	30,695	60,138	14,736	5.6M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.